CN1083721C - 逆转肝纤维化、肝硬化的中药复方及其制备方法 - Google Patents
逆转肝纤维化、肝硬化的中药复方及其制备方法 Download PDFInfo
- Publication number
- CN1083721C CN1083721C CN99103265A CN99103265A CN1083721C CN 1083721 C CN1083721 C CN 1083721C CN 99103265 A CN99103265 A CN 99103265A CN 99103265 A CN99103265 A CN 99103265A CN 1083721 C CN1083721 C CN 1083721C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- parts
- radix
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title abstract description 76
- 150000001875 compounds Chemical class 0.000 title description 36
- 210000004185 liver Anatomy 0.000 title description 15
- 206010016654 Fibrosis Diseases 0.000 title description 12
- 230000004761 fibrosis Effects 0.000 title description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 28
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000654 additive Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 208000006454 hepatitis Diseases 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 206010008909 Chronic Hepatitis Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000890 drug combination Substances 0.000 claims 4
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000000835 fiber Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 102000012432 Collagen Type V Human genes 0.000 description 2
- 108010022514 Collagen Type V Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- HYGYSIDIKIGPJA-UHFFFAOYSA-N chloroform;ethyl acetate;methanol Chemical compound OC.ClC(Cl)Cl.CCOC(C)=O HYGYSIDIKIGPJA-UHFFFAOYSA-N 0.000 description 1
- -1 decoction Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
分组 | 例数 | 平均病程(年) | 平均病程(年) | 慢性轻 | 乙型肝炎中 重 | 早期肝硬化 | ALT升高 | HBsAg(+) | HBeAg(+) |
治疗组对照组 | 8522 | 32.6233.54 | 5.65.3 | 3115 | 27 114 1 | 162 | 6115 | 8522 | 5914 |
治疗组1 | 治疗组2 | 治疗组3 | 治疗组4 | 对照组 | |
服用药剂临床症状改善(%) | 冲剂A78 | 冲剂B56 | 冲剂C62 | 冲剂D61 | 乙肝宁22 |
治疗组1 | 治疗组2 | 治疗组3 | 对照组 | ||
服用药剂临床症状改善(%) | 汤剂a62.96 | 汤剂b50.14 | 汤剂c46.29 | 丸剂d67.10 | 乙肝宁34.48 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99103265A CN1083721C (zh) | 1999-03-29 | 1999-03-29 | 逆转肝纤维化、肝硬化的中药复方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99103265A CN1083721C (zh) | 1999-03-29 | 1999-03-29 | 逆转肝纤维化、肝硬化的中药复方及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1268362A CN1268362A (zh) | 2000-10-04 |
CN1083721C true CN1083721C (zh) | 2002-05-01 |
Family
ID=5271185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99103265A Expired - Lifetime CN1083721C (zh) | 1999-03-29 | 1999-03-29 | 逆转肝纤维化、肝硬化的中药复方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1083721C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008080302A1 (fr) * | 2006-12-28 | 2008-07-10 | Beijing Yanhuang Qilin Biotechnology Development Co., Ltd. | NOUVELLE COMBINAISON D'UNE PROTÉINE DE FUSION CYTOKINE (IL-2/Fc) ET COMPOSÉ 861 DE MÉDECINE TRADITIONNELLE CHINOISE PERMETTANT D'AMÉLIORER LA RÉPONSE IMMUNITAIRE DU VACCIN CONTRE L'HÉPATITE B ET DE ROMPRE L'IMMUNOTOLÉRANCE DU VIRUS DE L'HÉPATIT |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI269656B (en) * | 2003-03-05 | 2007-01-01 | Original Image Co Ltd | Therapeutical composition for hepatitis C |
CN103191186A (zh) * | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | 丹参制剂在制备抗肝纤维化药物中的应用 |
CN103330881A (zh) * | 2012-02-07 | 2013-10-02 | 张雨 | 治疗慢性肝炎肝纤维化的中药丸剂及制备方法 |
CN111759968A (zh) * | 2020-07-13 | 2020-10-13 | 何欣怡 | 一种用于治疗肝硬化的中药组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076626A (zh) * | 1993-01-19 | 1993-09-29 | 李先文 | 肝病冲剂 |
CN1192922A (zh) * | 1998-04-10 | 1998-09-16 | 张俊才 | 一种治疗肝炎肝腹水的中成药 |
-
1999
- 1999-03-29 CN CN99103265A patent/CN1083721C/zh not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076626A (zh) * | 1993-01-19 | 1993-09-29 | 李先文 | 肝病冲剂 |
CN1192922A (zh) * | 1998-04-10 | 1998-09-16 | 张俊才 | 一种治疗肝炎肝腹水的中成药 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008080302A1 (fr) * | 2006-12-28 | 2008-07-10 | Beijing Yanhuang Qilin Biotechnology Development Co., Ltd. | NOUVELLE COMBINAISON D'UNE PROTÉINE DE FUSION CYTOKINE (IL-2/Fc) ET COMPOSÉ 861 DE MÉDECINE TRADITIONNELLE CHINOISE PERMETTANT D'AMÉLIORER LA RÉPONSE IMMUNITAIRE DU VACCIN CONTRE L'HÉPATITE B ET DE ROMPRE L'IMMUNOTOLÉRANCE DU VIRUS DE L'HÉPATIT |
Also Published As
Publication number | Publication date |
---|---|
CN1268362A (zh) | 2000-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101837065B (zh) | 抗肝炎、抗肿瘤及提高机体免疫功能的药物及其制备方法 | |
CN1186071C (zh) | 一种治疗慢性心衰的药物组合物及制备方法 | |
CN102416139B (zh) | 一种用于治疗乳腺疾病的中药组合物 | |
CN1323699C (zh) | 一种用于治疗痹病的外用膏药及其制备方法 | |
CN102362971B (zh) | 一种治疗冠心病中药及其有效化学组分的制备方法和制剂 | |
CN100415258C (zh) | 一种治疗白细胞减少的中药组合物及其制备和质量控制方法 | |
CN1083721C (zh) | 逆转肝纤维化、肝硬化的中药复方及其制备方法 | |
CN100371012C (zh) | 一种药物组合物及其制备方法和用途 | |
CN1861186A (zh) | 治疗慢性***的药物组合物及其制法和质量控制方法 | |
CN1927324A (zh) | 用于治疗妇女***中药制剂的制备方法 | |
CN1887324A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN101041037A (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN1256120C (zh) | 一种治疗慢性***的药物及其制备方法 | |
CN1923263A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN100336544C (zh) | 一种具有健肤美容作用的中药组合物及其制备方法 | |
CN1308032C (zh) | 一种治疗功能失调性子宫出血的药物组合物及其制备方法 | |
CN1242767C (zh) | 一种治疗肝纤维化疾病的中药复方制剂及其制备方法 | |
CN1294948C (zh) | 一种益气健脾滋补肝肾的药物及其制备方法 | |
CN1270755C (zh) | 一种治疗风湿类风湿性关节炎的药物组合物 | |
CN1923268B (zh) | 一种用于治疗鼻炎的药物组合物及其制备方法和质量控制方法 | |
CN100340267C (zh) | 一种治疗脂肪肝的中药制剂 | |
CN100342879C (zh) | 治疗肝纤维化的制剂及其制备方法 | |
CN1189207C (zh) | 一种提高人体免疫力的中药组合物及其制备方法 | |
CN1943717A (zh) | 一种治疗低血压症的中药组合物及其制备方法 | |
CN1943677A (zh) | 一种中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI HEP TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING FRIENDSHIP HOSPITAL ATTACHED TO CAPITAL MEDICAL UNIV. Effective date: 20120409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100050 XUANWU, BEIJING TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120409 Address after: 201203 Shanghai Zhangjiang hi tech Park 720 Cailun Road Lane 1, room 231 Patentee after: Shanghai HEP Medical Technology Co.,Ltd. Address before: 100050 No. 95, Yongan Road, Beijing, Xuanwu District Patentee before: Beijing Friendship Hospital Attached to Capital Medical Univ. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20020501 |